ResearcherCity University of Hong Kong, Shenzhen Research InstituteActive in the last 2 years
Kui Ming Chan
Matched on ORCID iD 0000-0001-6430-3340; OpenAlex author ID A5018282973. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 4
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 2
- Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D. Last author DOI 10.1016/j.celrep.2025.116596↗
- The H2BG53D oncohistone directly upregulates ANXA3 transcription and enhances cell migration in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41392-020-00219-2↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xin Wang · 2 shared papers, 2020–2025 · strength 0.32
- Paper Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohisto… DOI 10.1016/j.celrep.2025.116596↗
- Paper The H2BG53D oncohistone directly upregulates ANXA3 transcription and enhances cell migration in pancreatic ductal adeno… DOI 10.1038/s41392-020-00219-2↗
- Yi Ching Esther Wan · 2 shared papers, 2020–2025 · strength 0.32
- Paper Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohisto… DOI 10.1016/j.celrep.2025.116596↗
- Paper The H2BG53D oncohistone directly upregulates ANXA3 transcription and enhances cell migration in pancreatic ductal adeno… DOI 10.1038/s41392-020-00219-2↗
- Landon Long Chan · 1 shared paper, 2025 · strength 0.21
- Tiantian Qin · 1 shared paper, 2025 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.